Objective: The aim of this study was to examine if cholinergic receptor nicotinic beta 3 subunit () was a common genetic basis for both nicotine dependence and schizophrenia.
Methods: Two promoter single nucleotide polymorphisms (SNPs) were genotyped in 773 patients with schizophrenia and 302 healthy volunteers. Associations between smoking, schizophrenia, smoking+schizophrenia and were analyzed. The mRNA expression of in human brains was examined, and the expression correlations between and dopaminergic and GABAergic receptor genes were evaluated.
Results: The association between and smoking was significant in the total sample, less significant in the smoking with schizophrenia, and suggestive in the smoking without schizophrenia. had significant mRNA expression that was correlated with dopaminergic or GABAergic receptor expression in human brains. The two SNPs had significant cis-acting regulatory effects on mRNA expression.
Conclusions: Risk for smoking behavior was associated with . mRNA is abundant in human brain and could play important role in the pathogenesis of smoking behavior.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341072 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Can an Acceptance and Commitment Therapy-Based Smartphone App Help Individuals with Mental Health Disorders Quit Smoking?
Depress Anxiety
January 2025
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Background: Individuals with mental health disorders face major barriers in accessing smoking cessation care, often due to the stigmas associated with mental disorders and addiction. Consequently, accessible population-based smoking cessation interventions are needed for this vulnerable group.
Objective: This secondary analysis utilized data from a 12-month randomized trial to examine whether an acceptance and commitment therapy-based app (iCanQuit) demonstrated greater efficacy, engagement, and satisfaction compared to a United States (US) Clinical Practice Guidelines-based app (QuitGuide) in helping adults with mental health disorders quit smoking.
The effects of clinical and pharmacological factors on the ratio of clozapine to norclozapine in psychiatric patients.
Front Pharmacol
January 2025
Department of Psychiatry, Medical University of Warsaw, Warsaw, Poland.
Background: Due to its exceptional effectiveness, clozapine (CLO), whose metabolite is norclozapine (NCLO), is a drug of choice in the management of treatment-resistant schizophrenia. The purpose of this study was to assess the factors modifying the CLO/NCLO ratio (CNR).
Methods: A total of 446 blood samples (233 of which were drawn from females and 213 from males, aged from 18 to 77 years) were analyzed in this study.
Promoting Evidence-Based Tobacco Cessation Treatment in Community Mental Health Clinics: Results of a Pilot Implementation Study: Promouvoir le traitement de sevrage tabagique fondé sur des données probantes dans les cliniques communautaires de santé mentale : résultats d'une étude pilote de mise en œuvre.
Can J Psychiatry
January 2025
Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Objective: Tobacco smoking is the leading cause of preventable death among individuals with serious mental illness (SMI) but few persons with SMI are offered smoking cessation treatment. The purpose of this study was to pilot-test a multicomponent intervention to increase the delivery of evidence-based smoking cessation treatment in community mental health clinics (CMHCs).
Method: This study was carried out at five CMHCs in Maryland involving clinicians who participated in training in smoking cessation.
Effect of Valproate Coprescription on Clozapine Pharmacokinetics in Clinical Practice.
J Clin Psychopharmacol
January 2025
Department of Psychological Medicine, University of Otago, Wellington, New Zealand.
Background: Sodium valproate has been coprescribed with clozapine for seizure prophylaxis and for augmentation in treatment-refractory schizophrenia. However, the effect of valproate on clozapine metabolism and on the incidence of clozapine-related side effects is unclear.
Methods: We compared clozapine dose and plasma clozapine and N-desmethylclozapine (norclozapine) concentrations in smokers and nonsmokers of both sexes in samples submitted for clozapine therapeutic drug monitoring, 1996-2017 in relation to valproate coprescription.
Increased mortality risk in people with schizophrenia in Lithuania 2001-2020.
Schizophrenia (Heidelb)
January 2025
Laboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, Lithuania.
The aim of this study was to assess mortality risk in people with schizophrenia in Lithuania from 2001 and 2020. Cause-specific and all-cause mortality risk among patients with schizophrenia was assessed using a retrospective cohort study design. The cohort identified all patients with schizophrenia diagnosis (ICD-10 code F20) who were admitted to the Vilnius Republican Psychiatric Hospital from 1 January, 2001 to December 31, 2020.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!